Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03646162 · ClinicalTrials.gov registry record · Phase 2
Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
A Phase 2 study, sponsored by Veru.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT03646162 is a Phase 2 study that has completed, run by Veru. The registered enrollment target is 93 participants.
The verdict
NCT03646162, a Phase 2 study, has completed, sponsored by Veru.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate cancer
Interventions
- DRUG Placebo
- DRUG Veru-944
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2020-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03646162
The ClinicalTrials.gov registry entry for NCT03646162 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veru, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03646162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03646162 about?
NCT03646162 is a clinical study titled "Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer". Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate cancer
What is the current status of trial NCT03646162?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2018-09-14. Estimated completion is 2020-10-15.
What interventions are being tested in trial NCT03646162?
The interventions under investigation include: Placebo (DRUG), Veru-944 (DRUG).
Who is sponsoring clinical trial NCT03646162?
This trial is sponsored by Veru, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.